…Y terminar la semana científica coordinando el taller de cardiogenetica 🧬 🫀 con colegas del @cardiogenSAC y el GRAN maestro @jpocardio Gracias @SAC_54 por la invitación!

It has been a privilege to take part in the joint ACC–SAC session on “Scenarios in Sudden Cardiac Death,” discussing the role of genetics in SCD risk stratification. Grateful for the opportunity to share knowledge, & learn from outstanding colleagues @ChrisKramerMD @SamOJonesMD

Our findings suggest a disruption of the PD-L1/PD-1 axis in lymphocytic acute myocarditis, representing a potential target for future therapies. @CardioOncology @EricAdler17 jacc.org/doi/10.1016/j.jacad…

New publication in JACC: Case Reports: Recurrent cardiac myxomas in Carney complex. This case highlights the importance of early recognition, multimodality imaging, and lifelong multidisciplinary follow-up in CNC. @JACCJournals @imedCV @cardiohiba_resi @ManuChiodi @_RoBlanco

Optimizing Screening Intervals for At-Risk Relatives of Dilated Cardiomyopathy Carrying a TTNtv @FatkinLab @AChristensen112 @Dr_Pavia @ulvedreng @fernidom @ERNGUARDHeart @Ellenbroek ahajrnls.org/4xUupD2

🫀☕ Café con expertos | CUORE 26 Un espacio de encuentro para compartir experiencias, intercambiar conocimientos y conversar sobre casos clínicos junto a especialistas. 📅 13 de octubre 📍 Hilton BA | Puerto Madero ¡Los esperamos! #CUORE26 #Cardiología #CaféExpertos #HIBA

Gene editing isn't just science fiction anymore - it's moving into cardiovascular care. See the official ACC scientific statement to see where the field stands and what it means for the future of heart disease treatment jacc.org/doi/10.1016/j.jacc.… #JACC #cvGenetics #GeneEditing #CVD

🆕 SIMPOSIO MUERTE SÚBITA 🔗 Inscribite a través del link de nuestro perfil o us02web.zoom.us/meeting/regi… ¡Te esperamos! #imedcv #muertesubita #argenetics #hiba

Should we rethink genetic testing in older #DCM patients?🧬 In this cohort of 686 patients: 📍median age 50, 62.1% male 📍1 in 5 patients over 55 years of age were genotype-positive 📍30% of genotype-positive patients >55 years had high-risk genotypes 📍Similar risk of ventricular arrhythmias & end-stage HF vs younger patients 📚Read more in #EJHF @EJHFEiC :
doi.org/10.1093/ejhf/xuag055 #HeartFailure #Cardiomyopathy #Genetics @escardio @MarcoMetra @dougcannie @ath_bakalakos @ESC_Journals

#genotypefirst “Laminopathies: natural history and risk prediction of heart failure” 👉🏻 A must read in 🧬 🫀

The last 10 years have truly revolutionized our understanding of HCM and brought with it tremendous developments in new medicines Time to think beyond our historical simple assumptions This study nicely shows the need to adapt and sub-phenotype Asymptomatic HCM shouldn't only rely on symptoms. Evaluating MR/LA size/diastolic dysfunction, NTproBNP, and exercise induced PH allows one to truly phenotype this group further. jacc.org/doi/10.1016/j.jacc.… #CardioTwitter

🧬Precision medicine paradox: the more we stratify patients, more fragmented our datasets become In #rarediseases, this means overfitting, weak external validation & limited reproducibility Solution? Collaboration, shared standards & better biobanking 🌍🤝 thelancet.com/journals/landi…

🆕 Muy contento de compartir una nueva publicación de nuestro equipo 🙌 “The role of nutritional status, measured by serum albumin, as a prognostic factor in wild-type transthyretin amyloidosis” Los invito a leer el trabajo completo ⬇️ tandfonline.com/eprint/M9J7V…

🧬 Genetic testing in Dilated Cardiomyopathy: are we using it right? A new ESC consensus highlights a key shift: genetics in DCM is no longer just about family screening—it’s now central to clinical decision-making. 🔍 Key messages 🧠 Not just monogenic anymore DCM is increasingly seen as a continuum: Rare variants (high impact) common variants (polygenic background) environmental triggers ➡️ Disease = interaction, not a single mutation 🧬 Who should be tested? → almost everyone Genetic testing is recommended when results can impact: ✔️ diagnosis ✔️ prognosis ✔️ treatment (e.g. ICD decisions) ✔️ family screening ➡️ Even “acquired” DCM does NOT exclude genetics 📊 Yield is variable but meaningful ~8–36% overall up to 55% in familial DCM ➡️ Still clinically impactful despite imperfect yield ⚠️ Gene panels: bigger ≠ better Large panels increase VUS Limited gain in actionable variants ➡️ Focus on validated disease genes is key 🔥 Genotype matters clinically Some genes carry higher arrhythmic risk: LMNA, FLNC, DSP, RBM20, PLN ➡️ Can influence ICD decision-making beyond EF 🧩 The real paradigm shift: interpretation Genetic results must be read in context: phenotype environment (e.g. myocarditis, chemo, pregnancy) penetrance ➡️ A variant alone is NOT the diagnosis 👨‍👩‍👧 Family impact is huge Enables cascade screening Can discharge gene-negative relatives Opens reproductive options 💡 Take-home message Genetic testing in DCM is no longer optional or “nice to have”— it’s becoming a core part of precision cardiology. 👉 But its value depends entirely on how well we interpret it. #Cardiology #DCM #Genetics #Cardiomyopathy #PrecisionMedicine #HeartFailure #ESC #MedEd 🧬🫀 doi.org/10.1093/eurheartj/eh…

Hypertrophic cardiomyopathy: changing the paradigm of exercise prescription and competitive sport participation academic.oup.com/eurheartj/a…

Ya está disponible un nuevo número de @revistarac 📖 Compartimos un interesante artículo liderado por @Florcantora_ acerca del valor pronóstico del SLG medido en #whycmr en pacientes con MCH seguidos en @imedCV 🫀 👇👇👇 rac.sac.org.ar/index.php/rac…